Financiere De Tubize (TUB.BR) traded up 5.45 % during a 24 hours period ending at 11:16 PM Central Europe on Monday 26th. One Financiere De Tubize stock can currently be bought for about EUR 218.8 on popular exchanges. Current supply of Financiere De Tubize stocks is 44.5 mn. Financiere De Tubize has a current market capitalization of EUR 9.8 bn and approximately EUR 7.9 mn worth of Financiere De Tubize was traded on exchanges in the last 24 hours. Since last month end, Financiere De Tubize has traded 23.52 % up. Simple moving average of last 200 days is at EUR 206.91. The highest price of past 52 weeks was recorded at EUR 250.5 on 02/19/2026. 52 weeks low was at EUR 168.1 on 10/14/2026.
Here is how related stocks have performed in the past 24 hours:
D’ieteren (DIE.BR) traded down -0.8 % and now trades at EUR 175. Current market capitalisation for D’ieteren is EUR 9.1 bn. D’ieteren has a current price to earnings ratio of 21.32.
Warehouses De Pauw Sca (WDP.BR) traded down -0.67 % and now trades at EUR 19.27. Warehouses De Pauw Sca has a market capitalisation of EUR 5.1 bn. Current price/earnings ratio for Warehouses De Pauw Sca is 11.33.
Aedifica (AED.BR) traded up 0.08 % and now trades at EUR 63.1. Current market capitalisation for Aedifica is EUR 5.3 bn. Aedifica has a current price to earnings ratio of 5.56.
Lotus Bakeries (LOTB.BR) traded down -0.45 % and now trades at EUR 13,260. Lotus Bakeries has a market capitalisation of EUR 10.8 bn. Lotus Bakeries has a current price to earnings ratio of 56.64.
Ackermans & Van Haaren (ACKB.BR) traded down -0.24 % and now trades at EUR 261.6. Current market capitalisation for Ackermans & Van Haaren is EUR 8.3 bn. Ackermans & Van Haaren has a current price to earnings ratio of 12.98.
About Financiere De Tubize
Financiere de Tubize SA is a biopharmaceutical company that operates worldwide, with its main operations based in Brussels, Belgium. The company is involved in discovering and developing medicines and solutions for therapeutic areas such as neurology and immunology diseases. Its principal products include Cimzia for treating various inflammatory diseases like ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis; Briviact to treat epilepsy; Vimpat for the treatment of epilepsy partial-onset seizures; Neupro for treating Parkinson’s disease and restless legs syndrome; and Keppra for treating partial-onset seizures, primary generalized tonic-clonic seizures, and myoclonic seizures in epilepsy patients. Additionally, the company offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company’s products in pipeline include UCB0942 for drug resistant epilepsy; UCB3491 for infantile epilepsy; UCB0599 for Parkinson’s disease; UCB7858/UCB0159 for auto-inflammatory diseases; UCB6673 to treat immunological diseases; UCB4144/VR942 to treat asthma; seletalisib for treating Sjorgen’s syndrome; dapirolizumab pegol for systemic lupus erythematosus; bimekizumab to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis; rozanolixizumab to treat immune thrombocytopenia and myasthenia gravis; and romosozumab for post-menopausal osteoporosis and osteoporosis in men.